Predictors of Improvement in Storage Symptoms at Three Years After 120W GreenLight High Performance System Laser Treatment for Benign Prostate Hyperplasia
Restricted accessResearch articleFirst published online July, 2017
Predictors of Improvement in Storage Symptoms at Three Years After 120W GreenLight High Performance System Laser Treatment for Benign Prostate Hyperplasia
This study was conducted to investigate the indicators of recovery in storage symptoms after GreenLight High Performance System photoselective vaporization of the prostate (HPS-PVP) in men with benign prostate hyperplasia.
Methods:
A total of 155 men with a baseline subtotal storage symptom score of international prostate symptom score (sIPSS) greater than or equal to six, who underwent HPS-PVP and were followed up on for as much as 3 years, were included in this retrospective study. Surgical outcomes were evaluated at 1, 3, 6, 12, 24, and 36 months after surgery. Improvement of storage symptoms was defined as a reduction greater than or equal to 30% of sIPSS after surgery compared to the baseline.
Results:
The mean age was 67.5 ± 7.8 years and the preoperative median prostate-specific antigen, mean total prostate volume, and sIPSS were 1.95 (0.97–5.27) ng/mL, 52.1 ± 32.5 mL, and 9.6 ± 2.6, respectively. The mean improvement rate of sIPSS after 3 years was 34.4%. Age was only associated with an improvement of sIPSS in the multivariate analysis (odds ratio = 0.889, p = 0.008). The mean improvement rates of sIPSS according to age group (<65 vs ≥65) were 44.7% and 26.0%, respectively.
Conclusions:
Age can serve as an independent predictor of storage symptom improvement for as much as 3 years. Therefore, we suggest that older patients who are being considered candidates for surgical treatment should be further evaluated.
TasciAI, IlbeyYO, LuleciH, et al.120-W GreenLight laser photoselective vaporization of prostate for benign prostatic hyperplasia: Midterm outcomes. Urology, 2011; 78:134–140.
3.
ChoiYS, BaeWJ, KimSJ, et al.Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. Prostate Int, 2013; 1:169–176.
4.
SekiN, YukiK, TakeiM, YamaguchiA, NaitoS. Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. Neurourol Urodyn, 2009; 28:197–201.
PuppoP, BertolottoF, IntroiniC, GerminaleF, TimossiL, NaselliA. Bipolar transurethral resection in saline (TURis): Outcome and complication rates after the first 1000 cases. J Endourol, 2009; 23:1145–1149.
7.
ReichO. Bipolar transurethral resection of the prostate: What did we learn, and where do we go from here?. Eur Urol, 2009; 56:796–797.
8.
ZhangX, ShenP, HeQ, et al.Different lasers in the treatment of benign prostatic hyperplasia: A network meta-analysis. Sci Rep, 2016; 6:23503.
9.
SonH, RoYK, MinSH, ChooMS, KimJK, LeeCJ. Modified vaporization-resection for photoselective vaporization of the prostate using a GreenLight high-performance system 120-W Laser: The Seoul technique. Urology, 2011; 77:427–432.
10.
ChoSY, ParkS, JeongMY, RoYK, SonH. 120 W GreenLight High Performance System laser for benign prostate hyperplasia: 68 patients with 3-year follow-up and analysis of predictors of response. Urology, 2012; 80:396–401.
11.
NasproR, BachmannA, GillingP, et al.A review of the recent evidence (2006–2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol, 2009; 55:1345–1357.
12.
IrwinDE, MilsomI, HunskaarS, et al.Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol, 2006; 50:1306–1314; discussion 14–15.
13.
SextonCC, CoyneKS, KoppZS, et al.The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int, 2009; 103Suppl 3:12–23.
14.
HakkinenJT, HakamaM, HuhtalaH, et al.Impact of LUTS using bother index in DAN-PSS-1 questionnaire. Eur Urol, 2007; 51:473–477; discussion 7–8.
15.
PetersTJ, DonovanJL, KayHE, et al.The International Continence Society “Benign Prostatic Hyperplasia” Study: The botherosomeness of urinary symptoms. J Urol, 1997; 157:885–889.
16.
MironeV, ImbimboC, LongoN, FuscoF. The detrusor muscle: An innocent victim of bladder outlet obstruction. Eur Urol, 2007; 51:57–66.
17.
MebustWK, HoltgreweHL, CockettAT, PetersPC. Transurethral prostatectomy: Immediate and postoperative complications. a cooperative study of 13 participating institutions evaluating 3,885 patients. 1989. J Urol, 2002; 167(2 Pt 2):999–1003; discussion 4.
18.
BostanciY, KazzaziA, DjavanB. Laser prostatectomy: Holmium laser enucleation and photoselective laser vaporization of the prostate. Rev Urol, 2013; 15:1–10.
19.
ChoMC, HaSB, OhSJ, KimSW, PaickJS. Change in storage symptoms following laser prostatectomy: Comparison between photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP). World J Urol, 2015; 33:1173–1180.
20.
SekiN, KaiN, SeguchiH, TakeiM, YamaguchiA, NaitoS. Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology, 2006; 67:306–310.
21.
HuangT, YuYJ, QiJ, et al.Establishment and value assessment of efficacy prediction model about transurethral prostatectomy. Int J Urol, 2015; 22:854–860.
22.
SmithDP, WeberMF, SogaK, et al.Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,435 middle-aged and older Australian men: Population-based study. PLoS One, 2014; 9:e109278.
23.
Pannek J SM, BlokB, Castro-DiazD, Del PopoloG, KramerG, et al.Guidelines on Neurogenic Lower Urinary Tract Dysfunction. Arnhem, The Netherlands: European Association of Urology (EAU), 2011, p. 64.
24.
BaeJ, KangHW, LeeHW, LeeKS, ChoMC. Predictors of de novo urge urinary incontinence after photoselective vaporization of the prostate. World J Urol, 2016; 34:413–418.
25.
ChappleCR, MontorsiF, TammelaTL, WirthM, KoldewijnE, Fernandez FernandezE. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol, 2011; 59:342–352.
26.
RoehrbornCG, KaplanSA, LeporH, VolinnW. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis, 2011; 14:143–148.
27.
SaitoK, HisasueS, IdeH, et al.The impact of increased bladder blood flow on storage symptoms after holmium laser enucleation of the prostate. PLoS One, 2015; 10:e0129111.
28.
De NunzioC, BrassettiA, GacciM, et al.Patients with prostatic inflammation undergoing transurethral prostatic resection have a larger early improvement of storage symptoms. Urology, 2015; 86:359–365.
29.
BruskewitzRC, LarsenEH, MadsenPO, DorflingerT. 3-year followup of urinary symptoms after transurethral resection of the prostate. J Urol, 1986; 136:613–615.
30.
DollHA, BlackNA, McPhersonK, FloodAB, WilliamsGB, SmithJC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol, 1992; 147:1566–1573.
31.
HakenbergOW, PinnockCB, MarshallVR. Preoperative urodynamic and symptom evaluation of patients undergoing transurethral prostatectomy: Analysis of variables relevant for outcome. BJU Int, 2003; 91:375–379.
32.
SekiN, TakeiM, YamaguchiA, NaitoS. Analysis of prognostic factors regarding the outcome after a transurethral resection for symptomatic benign prostatic enlargement. Neurourol Urodyn, 2006; 25:428–432.
33.
HanDH, JeongYS, ChooMS, LeeKS. The efficacy of transurethral resection of the prostate in the patients with weak bladder contractility index. Urology, 2008; 71:657–661.
34.
MuzzonigroG, MilaneseG, MinardiD, YehiaM, GalosiAB, DellabellaM. Safety and efficacy of transurethral resection of prostate glands up to 150 ml: A prospective comparative study with 1 year of followup. J Urol, 2004; 172:611–615.
35.
LevinRM, MonsonFC, HaugaardN, et al.Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am, 1995; 22:263–283.
36.
IrwinDE, MilsomI, KoppZ, AbramsP, ArtibaniW, HerschornS. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: Impact of overactive bladder. Eur Urol, 2009; 56:14–20.
